Vericel Corp recently released its 10-Q report. The Cambridge, Massachusetts-based company develops, manufactures and sells cellular therapies and specialty biologic products in North America for ...
Unlock trusted, data-backed investing tools with TipRanks Premium, from analyst ratings and forecasts to breaking news and portfolio analysis. Discover high-conviction stock picks and new investing ...
Good day. And welcome to the MediWound First Quarter 2025 Earnings Call. All participants will be in listen-only mode [Operator Instructions]. Please note this event is being recorded. I would now ...
Enzymatic debridement employs proteolytic enzymes to selectively remove necrotic tissue (eschar) from burn wounds while preserving viable dermis. Historically derived from plant proteases such as ...
ABSTRACT: Objective: To evaluate the improvement effect of combined treatment of eschar abrasion, nanosilver dressing, and mussel mucin spray on wound healing in patients with second-degree burns, and ...
ABSTRACT: Objective: To evaluate the improvement effect of combined treatment of eschar abrasion, nanosilver dressing, and mussel mucin spray on wound healing in patients with second-degree burns, and ...
Early enzymatic burn debridement (EEBD) resulted in early complete eschar removal (ER) in more than 90% of adults with deep burns, according to results of the DETECT trial published in The Journal of ...
New drugs were approved for anaphylaxis, primary biliary cholangitis, prurigo nodularis, and more. Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults with prurigo ...
NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has expanded the approval of ...
Please provide your email address to receive an email when new articles are posted on . NexoBrid was approved for the treatment of deep partial-thickness and full-thickness thermal burns in adults in ...
The FDA approved anacaulase-bcdb for pediatric use, allowing its application for eschar removal in deep thermal burns for ages newborn to 18 years. The FDA has approved anacaulase-bcdb (NexoBrid) for ...
NexoBrid is a topically administered, bromelain-based biological product containing a sterile mixture of proteolytic enzymes. The Food and Drug Administration (FDA) has expanded the approval of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results